Nov 14, 2022 / 03:00PM GMT
Operator
Good morning, and welcome to the Oncolytics Biotech KOL webinar. (Operator Instructions) A question-and-answer session will follow the formal presentations. If you'd like to submit a question, you may do so by using the Q&A text box at the bottom of the webcast player or by e-mailing your questions to [email protected]. As a reminder, this call is being recorded, and a replay will be made available on the Oncolytics website following the conclusion of the event.
I'd now like to turn the call over to Matt Coffey, President and Chief Executive Officer of Oncolytics Biotech. Please go ahead, Matt.
Matthew C. Coffey - Oncolytics Biotech Inc. - President, CEO & Director
Thanks, Sarah, and thanks to all joining today's webcast. Our discussion today will center primarily around the exciting data reported from our GOBLET trials pancreatic cancer cohort at the SITC meeting last week. These data showed an objective response rate of 69%, including a confirmed complete response in 13 evaluable first-line advanced or metastatic pancreatic cancer
Oncolytics Biotech Inc at Society for Immunotherapy of Cancer Conference Transcript
Feb 08, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers